Clearmind Medicine Inc. announced that it has successfully manufactured batches of its drug candidate, MEAI-based molecule CMND-100, for use in its first in-human clinical trial. The trial will evaluate the psychedelic-derived drug candidate for the treatment of Alcohol Use Disorder (AUD). The drug candidate was produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements.
Clearmind Medicine Inc. Canadian Securities Exchange
Equities
CMND
CA1850534027
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |